A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia-Reference-Cited by-同舟云学术

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia

Published:2016-12-01 Issue:6 Volume:64 Page:e26351
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr Blood Cancer

Author:

Vormoor B.¹²,Veal G. J.¹,Griffin M. J.¹,Boddy A. V.¹,Irving J.¹,Minto L.¹,Case M.¹,Banerji U.³⁴,Swales K. E.³,Tall J. R.³,Moore A. S.³⁴,Toguchi M.⁵,Acton G.⁶,Dyer K.⁶,Schwab C.¹,Harrison C. J.¹,Grainger J. D.⁷⁸,Lancaster D.⁴,Kearns P.⁹,Hargrave D.¹⁰,Vormoor J.¹²

Affiliation:

1. Newcastle Cancer Centre at the Northern Institute for Cancer Research; Newcastle University; Newcastle upon Tyne UK

2. Great North Children's Hospital; Newcastle upon Tyne Hospitals NHS Foundation Trust; Newcastle upon Tyne UK

3. Cancer Research UK Cancer Therapeutics Unit; The Institute of Cancer Research; London U.K.

4. The Royal Marsden Hospital; Sutton UK

5. Astex Pharmaceuticals; Cambridge Science Park; Cambridge UK

6. Cancer Research UK Centre for Drug Development; London UK

7. Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK

8. Faculty of Medical & Human Sciences; University of Manchester; Manchester UK

9. Institute of Cancer and Genomic Medicine; University of Birmingham; Birmingham UK

10. Great Ormond Street Hospital for Children; London UK

Funder

Cancer Research UK

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference18 articles.

1. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study;Ko;J Clin Oncol,2010

2. Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group;Kaspers;J Clin Oncol,2103